MedTrace Logo

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

NCT04219319 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2022-08-16

No results posted yet for this study

Summary

A Phase I, Multicenter study to evaluate the safety, tolerability, and Efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+T Lymphocyte Tumor Patients.

Conditions

  • CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

Interventions

DRUG

Efficacy of LCAR-T2C CAR-T cells

CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor

Sponsors & Collaborators

  • Nanjing Legend Biotechnology Co. The First Affiliated Hospital of USTC west district；The First Affiliated Hospital of the Air Force Medical University

    collaborator UNKNOWN

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Wei Xu, PhD& MD · The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)

  • Kaiyang Ding, PhD& MD · Anhui Provincial Cancer Hospital

  • Guangxun Gao, PhD& MD · The First Affiliated Hospital of the Air Force Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-15
Primary Completion
2022-07-20
Completion
2022-07-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04219319 on ClinicalTrials.gov